New Zealand markets closed

Avidity Biosciences, Inc. (RNA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
48.14+3.42 (+7.65%)
At close: 04:00PM EDT
48.34 +0.20 (+0.42%)
After hours: 07:19PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close44.72
Open45.54
Bid48.04 x 400
Ask48.18 x 600
Day's range45.09 - 48.29
52-week range4.82 - 48.29
Volume986,739
Avg. volume1,552,379
Market cap5.188B
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)-2.96
Earnings date06 Aug 2024 - 12 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est61.56
  • PR Newswire

    Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on July 20, 2024, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 128,200 shares of its common stock and 22,100 restricted stock units ("RSUs") to six (6) new non-executive employees under the Avidity Bioscien

  • PR Newswire

    Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day

    Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is partnering with the FSHD Society and joining the global community of patients, caregivers, and healthcare providers to raise awareness of facioscapulohumeral muscular dystrophy in support of World FSHD Day. The FSHD Society is hosting a webinar with Avidity today at 1:00 p.m. ET to share recent unpre

  • Simply Wall St.

    Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

    Key Insights The projected fair value for Avidity Biosciences is US$46.34 based on 2 Stage Free Cash Flow to Equity...